NBDC Research ID: hum0381.v1

 

SUMMARY

Aims: We explore biomarkers of nivolumab efficacy and safety in patients with unresectable or recurrent thymic carcinoma. In order to perform multifaceted analysis using blood and tumor tissue specimens, pathological evaluation, pharmacokinetic, and molecular imaging analysis, genomic analysis, and immunomonitoring were performed.

Methods: We analyze immune-related genes (SNV, indel analysis and function prediction, copy number mutation analysis, etc.) by Immuno-PGx panel with peripheral blood cell components.

Participants/Materials: 15 patients with thymic carcinoma participating in the NCCH1505 study

 

Dataset IDType of DataCriteriaRelease Date
JGAS000588 NGS (Target Capture) Controlled-access (Type I) 2023/01/05

*Release Note

* Data users need to apply an application for Using NBDC Human Data to reach the Controlled-access Data. Learn more

 

JGAS000588

Participants/Materials thymic carcinoma (ICD10: C37) : 15 cases
Targets Target Capture
Target Loci for Capture Methods Immuno-PGx panel
Platform Illumina [NextSeq 500]
Library Source DNAs extracted from peripheral blood cells
Cell Lines -
Library Construction (kit name) Sure Select XT Library Prep Kit
Fragmentation Methods Ultrasonic fragmentation (Covaris)
Spot Type Paired-end
Read Length (without Barcodes, Adaptors, Primers, and Linkers) 101 bp
Japanese Genotype-phenotype Archive Dataset ID JGAD000715
Total Data Volume 17.1 GB (fastq)
Comments (Policies) NBDC policy

 

DATA PROVIDER

Principal Investigator: Hidehito Horinouchi

Affiliation: Department of Thoracic Oncology, Nantional Cancer Center Hospital

Project / Group Name: -

Funds / Grants (Research Project Number):

NameTitleProject Number
Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED) Study to Expand Indication of Nivolumab, an Anti-PD-1 Antibody, for Thymic Carcinoma and Thymoma JP17ck0106161

 

PUBLICATIONS

TitleDOIDataset ID
1 Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma doi: 10.3389/fonc.2022.966527 JGAD000715
2

 

USRES (Controlled-access Data)

Principal InvestigatorAffiliationCountry/RegionResearch TitleData in Use (Dataset ID)Period of Data Use